---
title: "BGM0504 Injection Achieves Phase III Clinical Trial Goals for Weight Loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285178242.md"
description: "Borui Pharmaceutical announced that its subsidiary has successfully achieved the goals in the Phase III clinical trial for the weight loss indication of its BGM0504 injection. This dual agonist of GLP-1 and GIP receptors shows potential for treating metabolic diseases, including blood sugar control and weight loss. The BGM0504 injection is also undergoing Phase III trials for type 2 diabetes in China."
datetime: "2026-05-05T09:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285178242.md)
  - [en](https://longbridge.com/en/news/285178242.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285178242.md)
---

# BGM0504 Injection Achieves Phase III Clinical Trial Goals for Weight Loss

On May 5, Borui Pharmaceutical announced that its wholly-owned subsidiary, Borui Pharmaceutical Co., Ltd., has successfully achieved the expected goals in the Phase III clinical trial for the weight loss indication of its independently developed BGM0504 injection. According to Jin10, BGM0504 is a dual agonist of GLP-1 and GIP receptors, which can activate downstream pathways of GIP and GLP-1, resulting in biological effects such as blood sugar control, weight loss, and treatment of non-alcoholic steatohepatitis, demonstrating potential for treating various metabolic diseases. Additionally, the BGM0504 injection is currently in Phase III clinical trials for the type 2 diabetes indication in China.

### Related Stocks

- [688166.CN](https://longbridge.com/en/quote/688166.CN.md)

## Related News & Research

- [02:32 ETBrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States](https://longbridge.com/en/news/280422627.md)
- [Richter, Adalvo expand tirzepatide co-development partnership for diabetes, obesity care](https://longbridge.com/en/news/295062917.md)
- [Humanwell unit Yichang Renfu wins China nod for labor pain trial of sufentanil injection](https://longbridge.com/en/news/295637927.md)
- [Rubellite Energy forecasts FY2026 heavy oil sales of 8,500-9,200 bpd](https://longbridge.com/en/news/295406088.md)
- [KPRMILL: Strong revenue and profit growth driven by textile and sugar segments, with unqualified audit review](https://longbridge.com/en/news/295373967.md)